Find policies, billing codes, payers, states, and providers
Loading...
Find policies, billing codes, payers, states, and providers
CPT 87900: Viral Drug Susceptibility and Phenotype Prediction
CPT-87901-HIV-1-GENOTYPE-REVERSE-TRANSCRIPTASE-PROTEASE-ANALYSISCPT 87901: HIV‑1 Genotype — Protease and Reverse Transcriptase Sequencing
CPT-87902-HEPATITIS-C-GENOTYPE-NUCLEIC-ACID-TESTING-TECHNICALCPT 87902: Hepatitis C Virus Genotype by Nucleic Acid Analysis
CPT-87903-HIV-1-DRUG-RESISTANCE-NUCLEIC-ACID-ANALYSISCPT 87903: HIV-1 Drug Resistance Testing, Culture-Based
CPT-87904-HIV-1-DRUG-RESISTANCE-ADDITIONAL-DRUG-TESTINGCPT 87904: HIV‑1 Drug Resistance Test, Additional Drug
CPT-87905-ENZYMATIC-ACTIVITY-TESTING-INFECTIOUS-AGENT-TECHNICALCPT 87905: Enzymatic Activity Test for Non-Viral Infectious Agents
CPT-87906-HIV-1-GENOTYPE-NUCLEIC-ACID-NON-RT-PROTEASE-REGIONSCPT 87906: HIV‑1 Genotype by Nucleic Acid (non-RT/protease)
CPT-87910-CMV-GENOTYPE-NUCLEIC-ACID-ANALYSISCPT 87910: CMV Genotype Analysis by Nucleic Acid Testing
CPT-87912-HEPATITIS-B-GENOTYPE-ANALYSIS-NUCLEIC-ACIDCPT 87912: Hepatitis B Virus Genotype Analysis
CPT-87913-SARS-COV-2-GENOTYPE-ANALYSIS-NEXT-GENERATION-SEQUENCINGCPT 87913: SARS–CoV–2 Genotype Analysis by Next‑Generation Sequencing
Showing 1–10 of 11
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.